126 related articles for article (PubMed ID: 38498992)
1. The risk factors and clinical outcomes in hepatitis B seropositive and seronegative renal transplant patients.
Tsai YL; Chung MH; Lin NC; Chen CY; Lin YP; Tsai MT; Tsai HL; Chen YA; Ou SM; Chu CJ; Wu TH; Tsai CY
Am J Nephrol; 2024 Mar; ():. PubMed ID: 38498992
[TBL] [Abstract][Full Text] [Related]
2. Outcome after kidney transplantation in hepatitis B surface antigen-positive patients.
Mo H; Min S; Han A; Jung IM; Ha J
Sci Rep; 2021 Jun; 11(1):11744. PubMed ID: 34083686
[TBL] [Abstract][Full Text] [Related]
3. Risk of hepatitis B reactivation in hepatitis B surface antigen seronegative and core antibody seropositive kidney transplant recipients.
Querido S; Weigert A; Adragão T; Rodrigues L; Jorge C; Bruges M; Machado D
Transpl Infect Dis; 2019 Feb; 21(1):e13009. PubMed ID: 30295412
[TBL] [Abstract][Full Text] [Related]
4. High pretransplant HBV level predicts HBV reactivation after kidney transplantation in HBV infected recipients.
Kim JM; Park H; Jang HR; Park JB; Kwon CH; Huh W; Lee JH; Kim SJ; Joh JW
Ann Surg Treat Res; 2014 May; 86(5):256-63. PubMed ID: 24851227
[TBL] [Abstract][Full Text] [Related]
5. Outcomes and risk factors for hepatitis B virus (HBV) reactivation after kidney transplantation in occult HBV carriers.
Chen GD; Gu JL; Qiu J; Chen LZ
Transpl Infect Dis; 2013 Jun; 15(3):300-5. PubMed ID: 23473005
[TBL] [Abstract][Full Text] [Related]
6. A multicenter evaluation of hepatitis B reactivation with and without antiviral prophylaxis after kidney transplantation.
Shaikh SA; Kahn J; Aksentijevic A; Kawewat-Ho P; Bixby A; Rendulic T; Park JM
Transpl Infect Dis; 2022 Feb; 24(1):e13751. PubMed ID: 34725887
[TBL] [Abstract][Full Text] [Related]
7. Reactivation of Hepatitis B virus in kidney transplant recipients with previous clinically resolved infection: A single-center experience.
Meng C; Belino C; Pereira L; Pinho A; Sampaio S; Tavares I; Bustorff M; Sarmento A; Pestana M
Nefrologia (Engl Ed); 2018; 38(5):545-550. PubMed ID: 29709320
[TBL] [Abstract][Full Text] [Related]
8. Rituximab and hepatitis B reactivation in HBsAg-negative/ anti-HBc-positive kidney transplant recipients.
Lee J; Park JY; Huh KH; Kim BS; Kim MS; Kim SI; Ahn SH; Kim YS
Nephrol Dial Transplant; 2017 Apr; 32(4):722-729. PubMed ID: 28339910
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis B virus among hematopoietic stem cell transplant recipients: Antiviral impact in seroconversion, engraftment, and mortality in a Latin American center.
Buzo BF; Ramos JF; Marques Rossetti RA; Salles N; Mendrone-Júnior A; Rocha V; de Seixas Santos Nastri AC
Transpl Infect Dis; 2020 Apr; 22(2):e13243. PubMed ID: 31901206
[TBL] [Abstract][Full Text] [Related]
10. Incidence, risk factors, and clinical outcomes of HBV reactivation in non-liver solid organ transplant recipients with resolved HBV infection: A systematic review and meta-analysis.
Yin S; Zhang F; Wu J; Lin T; Wang X
PLoS Med; 2023 Mar; 20(3):e1004196. PubMed ID: 36920988
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis B virus reactivation in patients with resolved hepatitis B virus infection receiving chemotherapy or immunosuppressive therapy.
Su YC; Lin PC; Yu HC; Wu CC
Eur J Gastroenterol Hepatol; 2018 Aug; 30(8):925-929. PubMed ID: 29621049
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis B-related outcomes following direct-acting antiviral therapy in Taiwanese patients with chronic HBV/HCV co-infection.
Yeh ML; Huang CF; Huang CI; Holmes JA; Hsieh MH; Tsai YS; Liang PC; Tsai PC; Hsieh MY; Lin ZY; Chen SC; Huang JF; Dai CY; Chuang WL; Chung RT; Yu ML
J Hepatol; 2020 Jul; 73(1):62-71. PubMed ID: 32061869
[TBL] [Abstract][Full Text] [Related]
13. Risk of Reverse Seroconversion of Hepatitis B Virus Surface Antigen in Rituximab-Treated Non-Hodgkin Lymphoma Patients: A Large Cohort Retrospective Study.
Hsiao LT; Chiou TJ; Gau JP; Yang CF; Yu YB; Liu CY; Liu JH; Chen PM; Tzeng CH; Chan YJ; Yang MH; Huang YH
Medicine (Baltimore); 2015 Aug; 94(32):e1321. PubMed ID: 26266374
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis B virus infection in heart transplant recipients in a hepatitis B endemic area.
Ko WJ; Chou NK; Hsu RB; Chen YS; Wang SS; Chu SH; Lai MY
J Heart Lung Transplant; 2001 Aug; 20(8):865-75. PubMed ID: 11502409
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis B Virus Vaccination after Allogeneic Hematopoietic Cell Transplantation Prevents Post-Transplantation Hepatitis B Virus Reactivation.
Hammond SP; Ho VT; Marty FM
Transplant Cell Ther; 2022 Jul; 28(7):402.e1-402.e5. PubMed ID: 35413458
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis B Virus Reactivation in Kidney Transplant Recipients Treated With Belatacept.
Schwarz C; Morel A; Matignon M; Grimbert P; Rondeau E; Ouali N; François H; Mesnard L; Petit-Hoang C; Rafat C; Dahan K; Luque Y
Kidney Int Rep; 2023 Aug; 8(8):1531-1541. PubMed ID: 37547512
[TBL] [Abstract][Full Text] [Related]
17. Anti-HBc impacts on the risk of hepatitis B reactivation but not on survival of solid-organ transplant recipients.
Álvarez-López P; Riveiro-Barciela M; Oleas-Vega D; Flores-Cortes C; Román A; Perelló M; Berastegui C; Castells L; Esteban R; Buti M
Medicine (Baltimore); 2020 Feb; 99(9):e19407. PubMed ID: 32118794
[TBL] [Abstract][Full Text] [Related]
18. Pretransplant Hepatitis B Viral Infection Increases Risk of Death After Kidney Transplantation: A Multicenter Cohort Study in Korea.
Lee J; Cho JH; Lee JS; Ahn DW; Kim CD; Ahn C; Jung IM; Han DJ; Lim CS; Kim YS; Kim YH; Lee JP
Medicine (Baltimore); 2016 May; 95(21):e3671. PubMed ID: 27227927
[TBL] [Abstract][Full Text] [Related]
19. Rituximab increases the risk of hepatitis B virus reactivation in non-Hodgkin lymphoma patients who are hepatitis B surface antigen-positive or have resolved hepatitis B virus infection in a real-world setting: a retrospective study.
Tsai YF; Yang CI; Du JS; Lin MH; Tang SH; Wang HC; Cho SF; Liu YC; Su YC; Dai CY; Hsiao HH
PeerJ; 2019; 7():e7481. PubMed ID: 31565551
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis B virus reactivation in kidney transplant patients with resolved hepatitis B virus infection: Risk factors and the safety and efficacy of preemptive therapy.
Mei T; Noguchi H; Hisadome Y; Kaku K; Nishiki T; Okabe Y; Nakamura M
Transpl Infect Dis; 2020 Apr; 22(2):e13234. PubMed ID: 31856328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
